Multiple Myeloma

Keith Stewart, MB, CHB, professor of medicine, consultant, Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, discusses the role of transplant in patients with multiple myeloma.

Rafael Fonseca, MD, hematologist, Mayo Clinic, discusses the use of fluorescence in situ hybridization (FISH) in diagnosing patients with myeloma.

Koen van Besien, MD, PhD, director, Stem Cell Transplant Program, professor of medicine, Weill Cornell Medical College, attending physician, NewYork-Presbyterian Hospital, discusses use of autologous stem cell transplantation in large cell lymphoma and multiple myeloma.

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses novel agents for the treatment of patients with multiple myeloma.

The European Commission has approved denosumab for the prevention of skeletal-related events in adult patients with multiple myeloma.

Noa Biran, MD, discusses treatment breakthroughs and emerging advances in the field of multiple myeloma.

Noa Biran, MD, physician, Multiple Myeloma Division, John Theurer Cancer Center, discusses doublets versus triplets in the treatment of patients with multiple myeloma.

C. Ola Landgren, MD, PhD, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses the superiority of 3-drug regimens and the next steps in the treatment of patients with multiple myeloma.

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses ongoing phase III studies in patients with multiple myeloma.

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses differentiating patients with smoldering myeloma and multiple myeloma.

Jeffrey Wolf, MD, clinical professor, Department of Medicine, director, Myeloma Program, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses treatment options for patients with multiple myeloma.

Jesus Berdeja, MD, provides an update on practice-changing data for the treatment of patients with multiple myeloma.

Joshua Richter, MD, a hematologist/oncologist specializing in multiple myeloma at the John Theurer Cancer Center, discusses toxicities in the treatment of patients with multiple myeloma.

Jesus Berdeja, MD, reflects on pivotal studies in multiple myeloma and discussed potential advancements in the upcoming year.

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses the future of treatment for patients with myeloma.

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of denosumab (Xgeva) for the prevention of skeletal-related events in patients with multiple myeloma.

Phyllis McKiernan, a nurse practitioner at John Theurer Cancer Center, Hackensack Medical Center, discusses the outcomes of a study investigating autologous stem cell transplantation (ASCT) in elderly patients with multiple myeloma.

Pomalidomide in combination with low-dose dexamethasone induced an overall response rate of up to 39% in patients with relapsed/refractory multiple myeloma with renal impairment.

Denosumab was noninferior to zoledronic acid in preventing skeletal-related event in patients with newly diagnosed multiple myeloma.

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses molecular profiling in patients with multiple myeloma.

Nina Shah, MD, associate professor, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Comprehensive Cancer Center, discusses the potential of chimeric antigen receptor T-cell therapy in myeloma.

Cristina Gasparetto, MD, discusses selinexor in combination with daratumumab and dexamethasone in patients with relapsed/refractory myeloma.

John Richter, MD, discusses the findings form the self-reported symptom and psychological survey in patients with multiple myeloma.

Mark W. Bustoros, MD, Dana-Farber Cancer Institute, discusses the role of next-generation sequencing for patients with multiple myeloma.

Adding pomalidomide to the combination of bortezomib and low-dose dexamethasone led to a significant improvement in progression-free survival in patients with relapsed/refractory myeloma with prior exposure to lenalidomide.

Joshua Richter, MD, a hematologist/oncologist specializing in multiple myeloma at the John Theurer Cancer Center, discusses the findings from a study on the incidence and survival impact of self-reported symptom and psychological distress for patients with multiple myeloma.

Cristina Gasparetto, MD, assistant professor of medicine, member of the Duke Cancer Institute, discuss the efficacy of selinexor in combination with dexamethasone for the treatment of patients with multiple myeloma.

The European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending a label variation for carfilzomib in patients with relapsed/refractory multiple myeloma.

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses next steps with the CAR T-cell therapy bb2121 in multiple myeloma.

The combination of carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone extended overall survival for patients with relapsed or refractory multiple myeloma by nearly 8 months compared with lenalidomide and dexamethasone alone.